A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery

Prostaglandins Leukot Essent Fatty Acids. 1992 Feb;45(2):121-4. doi: 10.1016/0952-3278(92)90227-a.

Abstract

We examined the effect of a novel antihypertensive diuretic, torasemide, on the vasoconstriction induced by TXA2 in the isolated canine coronary artery. Carbocyclic thromboxane A2 (CTA2), a stable analogue of the potent coronary vasoconstrictor thromboxane A2, exhibited a slow onset and progressive contraction of isolated canine coronary arteries at 2 x 10(-8) M. Torasemide (10(-7) approximately 10(-4) M) elicited a dose-dependent vasodilating action in the isolated canine coronary arteries contracted by CTA2, whereas indapamide or furosemide had little effect on this preparation. The maximum vasodilating response to torasemide was 45 +/- 12% of vasodilating effect induced by 10(-4) M papaverine. These results suggest that torasemide is a promising antihypertensive agent with a coronary protective effect.

MeSH terms

  • Animals
  • Coronary Vessels / drug effects*
  • Diuretics / pharmacology
  • Dogs
  • Female
  • In Vitro Techniques
  • Male
  • Sulfonamides / pharmacology*
  • Thromboxane A2 / antagonists & inhibitors*
  • Thromboxane A2 / pharmacology
  • Torsemide
  • Vasoconstriction / drug effects*
  • Vasodilation / drug effects

Substances

  • Diuretics
  • Sulfonamides
  • Thromboxane A2
  • Torsemide